Rituximab First-Line PV — SCE Dermatology MCQ

Correct answer: C — Higher complete remission rates with lower cumulative corticosteroid exposure — RITUX 3 showed superior outcomes for Rituximab + low-dose Prednisolone versus Prednisolone alone

The correct answer is C, higher complete remission rates with lower cumulative corticosteroid exposure, because the RITUX 3 trial (Joly et al) demonstrated that first-line rituximab plus low-dose prednisolone produced markedly superior complete remission at 24 months compared with prednisolone alone, with a much lower total glucocorticoid dose. This is the key discriminating feature in the stem: the question specifically references RITUX 3 evidence, and that trial's primary outcome was disease control off treatment, not speed of response, cost, route, or monitoring burden. Rituximab depletes CD20 positive B cells, removing the source of pathogenic desmoglein autoantibodies, which allows corticosteroids to be tapered faster and to a lower cumulative dose, reducing steroid-related morbidity. British Association of Dermatologists guidance reflects this trial evidence in supporting rituximab use in pemphigus vulgaris management. Why the other options are wrong: B. Faster onset of action: rituximab requires B cell depletion and antibody clearance over weeks to months, so corticosteroids remain necessary initially for rapid disease control; onset is not faster than steroids. D. Lower cost: rituximab is a biologic infusion and is substantially more expensive per course than conventional oral immunosuppressants, though this may be offset by reduced steroid complications. A. Oral administration: rituximab is given as an intravenous infusion, not orally, unlike conventional agents such as prednisolone or azathioprine. E. No monitoring required: rituximab requires monitoring for infusion reactions, infection risk, hepatitis B reactivation, and hypogammaglobulinaemia, so monitoring needs are not reduced. Key point: RITUX 3 established that first-line rituximab plus low-dose prednisolone achieves higher sustained complete remission with significantly less cumulative corticosteroid exposure than prednisolone alone in pemphigus vulgaris.

Reference: British Association of Dermatologists guidelines for the management of pemphigus vulgaris 2017, British Journal of Dermatology (Harman et al, 2017), https://onlinelibrary.wiley.com/doi/10.1111/bjd.15930